Rationale: Viral myocarditis results from an adverse immune response to cardiotropic viruses, which causes irreversible myocyte destruction and heart failure in previously healthy people. The involvement of microRNAs and their usefulness as therapeutic targets in this process are unknown.
mune system. 2 Here, we investigated the hitherto unknown role of microRNAs as possible molecular drivers in the pathogenesis of VM.
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MicroRNAs (miRNAs) represent a class of small noncoding RNAs that control the expression of entire networks of complementary transcripts. 3 In the heart, miRNAs have been shown to be necessary for normal embryonic development 4 and homeostasis. 5 While individual miRNAs have been linked to specific cardiac diseases-including hypertrophic remodeling (miR-199, 6 miR-208a 7 ) , fibrosis (miR-21, 8 miR-29 9 ), and ischemia (miR-24, 10 miR-499, 11 miR-92a 12 )-the role of miRNAs in inflammatory cardiac processes and more specifically during VM has not yet been established. Here, we report diverging expression profiles of miRNAs in VMsusceptible versus VM-resistant mouse strains. Among others, miR-155, a known proinflammatory regulator of myeloid and lymphoid immune cell function, [13] [14] [15] is consistently upregulated in human and mouse cardiac samples of VM during the acute inflammatory phase, and is primarily expressed by recruited inflammatory cells. Pharmacological inhibition of miR-155 by a systemically delivered locked nucleic acid (LNA)-anti-miR-a class of miRNA inhibitors that has been successfully used in primate studies 16, 17 and is currently used in human clinical trials-attenuates cardiac inflammation and necrosis in acute mouse VM, and reduces mortality and contractile dysfunction in long-term follow-up. These data identify miR-155 as a contributor to the adverse inflammatory response and a potential therapeutic target in VM.
Methods
An expanded Methods section is available in the Online Data Supplement.
Animal Studies
All mouse experiments were performed according to the local relevant guidelines. For viral myocarditis (VM) miRNA profiling experiments, 4-week-old male susceptible C3H mice or resistant N-strain C57Bl/6 mice 18 (Harlan, Boxmeer, The Netherlands) were used (nϭ3 per group). For microRNA knockdown in vivo, mice received 3 iv injections per week (25 mg/kg/injection) of a 15-mer LNA-anti-miR oligonucleotide targeting mmu-miR-155 or an LNA control. Chronic treatment for the 7-week follow-up included 2 weeks of high-dose treatment (25 mg/kg/injection iv) followed by 5 weeks of low-dose treatment (5 mg/kg/injection ip). Group sizes were at least nϭ6 for sham and nϭ11 for VM groups in the 1-week analysis, nϭ6 per sham and nϭ8 for VM for flow cytometry, and nϭ6 for sham and nϭ20 for VM in the 7-week analysis.
Patient Material
All human material was obtained during routine clinical sampling and available for research purposes in accordance with the Declaration of Helsinki and the ethical committee at Maastricht University Medical Center. MicroRNAs were profiled in right ventricular septal biopsies from patients with acute myocarditis (nϭ4) with a definite clinical history of myocarditis 1 and confirmed virus presence in the cardiac biopsies (Online Table I ). Controls (nϭ6) consisted of age-matched patients with unexplained ventricular tachy-arrhythmias but with a normal ejection fraction and the absence of systemic or cardiac inflammation or virus presence at the time of biopsy (Online Table I ).
In Situ Hybridization
In situ hybridization was performed as described previously. 19, 20 Details are available the Methods section in the online-only Data Supplement.
MicroRNA and Messenger RNA Expression Array Analysis
For microRNA array analysis, total RNA from human biopsies was hybridized to Illumina Human miRNAv2 Expression Panel arrays by ServiceXS (Leiden, The Netherlands) and total RNA from mouse left ventricles was hybridized to Paraflo arrays (LC Sciences, Houston, TX). Raw data and detailed information about arrays analyses are available in the Methods section in the online-only Data Supplement. Messenger RNA analysis from hearts of LNA control and LNA-anti-miR-155-treated mice (sham and 7 days post-CVB3 injection) was performed by hybridizing to Affymetrix GeneChip Mouse Gene 1.0 ST arrays.
Statistical Analyses
Statistical analyses for miRNA arrays were performed in R. Analyses for experimental work were performed using GraphPad Prism 5.0d for Macintosh (GraphPad Software, Inc., La Jolla, CA). Pearson's correlation coefficients were determined to study correlations of quantitative variables in data sets with a Gaussian distribution. Comparisons between 2 groups were performed with 2-tailed Student t testing for Gaussian data or Mann-Whitney tests for non-Gaussian data. For comparisons of more than 2 groups, 1-way analysis of variance was used, followed by post hoc testing using Bonferroni correction for more groups. Probability values below 0.05 were considered statistically significant. Data are presented as meanϮSEM unless otherwise indicated.
Results

Cardiac miRNA Profiles During Coxsackievirus B3-Induced Murine Viral Myocarditis
To identify miRNAs with a role in acute viral myocarditis (VM) we first analyzed miRNA expression profiles of Coxsackievirus B3 (CVB3)-induced VM in mice. To differentiate between miRNA changes associated with viral infection and inflammation, we used 2 mouse strains: C3H mice that are highly susceptible to CVB3-induced myocarditis and C57Bl/6N mice that are resistant to CVB3-induced cardiac inflammation despite similar accumulation of viral genomes in the heart. 18 Cardiac miRNA expression was evaluated at baseline and at days 4 and 7 after CVB3 inoculation to study viral replication before and after the onset of macroscopic inflammation, respectively. Histological analysis confirmed extensive myocyte necrosis and leukocyte infiltration in C3H mice at 7 days, whereas only small patches of inflammation were observed in C57Bl/6N animals ( Figure 1A and 1B) . Expression of CVB3 virus was detected in all mice at days 4 and 7, and did not significantly differ between strains ( Figure 1C ). A heat map of cardiac miRNA expression during VM in both strains shows diverging expression between the strains for clusters of miRNAs, most prominently after the onset of inflammation at day 7 after infection ( Figure 1D through 1F; Online Figures IA and IIA). The most extensive differences were observed in the highly inflamed C3H hearts at 7 days in comparison with sham, where miRNA changes were markedly larger than in the mildly inflamed C57Bl/6N hearts: 78 versus 221 miRNAs were differentially regulated at 7 days in comparison with sham in C3H mice and C57Bl/6N mice, respectively. The majority of these differentially regulated miRNAs in C57Bl/6N animals overlapped with the C3H miRNA changes, indicating consistency in the inflammatory response that was mild but not absent in C57Bl/6N, as shown in Figure 1A and 1B.
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At day 4 after infection, during cardiac viral replication but before infiltration of immune cells, 11 (resistant C57Bl/6N) and 16 miRNAs (susceptible C3H) were differentially regulated in comparison with sham. These miRNA changes showed little overlap with day 7 changes in both strains, indicating that day 4 differences reflect biological signaling distinct from inflamma-tion (Online Figure IB) . Importantly, the miRNAs differentially expressed at day 4 did not overlap between species, reflecting the diverging molecular response to CVB3 infection that may determine the severity of cardiac inflammation.
Individual Cardiac miRNAs Are Regulated During Coxsackievirus B3-Induced Murine Viral Myocarditis
We next focused on individual dysregulated miRNAs. Notably, miRNAs that are well known for their roles in the immune system and inflammatory responses 21 were among the most strongly upregulated miRNAs during the inflammatory phase of VM (C3H mice at day 7), including miR-155, miR-21, miR-146a, miR-146b, and miR-223 (Online Tables  III and IV; Online Figures II and III ). In addition, miR-106a and -130b were strongly upregulated, whereas miR-361, miR-30e*, miR-149, miR-574 to 3p, and myocyte-enriched miR-208a and miR-499 were significantly downregulated. The downregulation of miR-208a and miR-499 may reflect their known regulation in cardiac stress, 7, 11 or may reflect necrosis present in myocarditis hearts. In support of the latter, other myocyte miRNAs (myomiRs) were either downregu- A number of miRNAs were regulated only in VM-resistant C57Bl/6N mice and may be involved in disease susceptibility. Dysregulated miRNAs at day 4 in C57Bl/6N included miR-483*, miR-411, miR-135*, miR-300, and miR-140. In addition, miR-93* and miR-17* were upregulated at both days 4 and 7 after infection. Furthermore, miR-361 was consistently found downregulated in both strains as early as 4 days postinfection and persisting until day 7 (Online Tables  III and IV) .
We selected a set of microRNAs with interesting profiles in either C3H or C57Bl/6N VM for qRT-PCR verification of microarray expression profiles. Overall, qRT-PCR measurements confirmed expression patterns observed by microarray analysis, showing significant upregulation of miR-155 (5.9fold), miR-146b (13.9-fold), and miR-21 (12.8-fold), as well as downregulation of miR-499 (1.9-fold) (Online Figure III) .
Cardiac MicroRNA Expression During Human Viral Myocarditis
In parallel, we analyzed miRNA expression in a set of right ventricular septal biopsies obtained from patients with acute VM and controls. A total of 107 miRNAs were differentially expressed between VM and control hearts, of which 21 miRNAs were upregulated and 37 miRNAs were downregulated by more than 1.5-fold ( Figure 2A Table V ). Among the most upregulated miRNAs were miR-155 (3.5-fold, PϽ10 Ϫ4 ) and miR-146b (11.9-fold, PϽ0.01), besides miR-511 (5-fold), a stimulator of toll-like receptor (TLR) signaling, 22 miR-212 (2.6-fold), involved in cardiomyocyte hypertrophy, 23 and the relatively unknown miR-889 (3.2-fold). Downregulated miRNAs included the inflammatory miR-106a (2.3-fold) and miR-93 (1.6-fold), and miR-361 to 3p (2.3-fold).
We compared mouse and human miRNA profiles during VM. Out of the 107 miRNAs differentially expressed in human VM, 66 miRNAs could be matched to their mouse homologues, of which 16 were also differentially expressed during mouse VM ( Figure 2B and 2C, Online Figure VB, and Online Table V ). These 16 miRNAs included miR-155, miR-146b, miR-21, and miR-501 to 3p (consistently upregulated) and miR-103a, miR-107, miR-99b, miR-149, miR-30a*, and miR-30e* (consistently downregulated).
Interestingly, the miR-499(-5p) was significantly downregulated in mouse, but not in human, VM, while its opposite strand miR-499 to 3p was the most downregulated miRNA in humans (3.1-fold, PϽ0.05) (Online Figures IIIC and VC) . MyomiRs that were regulated in humans included miR-133a and miR-133b, which were both significantly downregulated (Online Table V ). In general, miRNAs with a role in inflammation were dysregulated most robustly, while myo-miRs were predominantly downregulated during VM.
MiR-155 Is Expressed by Infiltrating Inflammatory Cells in Both Mouse and Human VM
Since miR-155 was strongly and significantly upregulated in hearts of both VM-susceptible mice and VM patients, we focused on its expression and role in the pathogenesis of VM. To address which cells produce miR-155 during VM, we performed in situ hybridization (ISH) on sections of mouse hearts and human cardiac biopsies. Perinuclear miR-155 staining was observed specifically in inflammatory patches, while no in situ signal was detected in adjacent myocardium. When hybridization was performed with a scrambled control probe, no signal was detected, indicating that miR-155 detection was sequence specific ( Figure 3A and Online Figure VI ). To learn whether miR-155 preferentially localized in macrophages or T lymphocytes, we stained sequential sections for miR-155, CD45, Mac3, and CD3 ( Figure 3B ). Staining for miR-155 colocalized with CD45-positive leukocytes, including many Mac3-positive macrophages and CD3positive T lymphocytes. Double staining for miR-155 and CD3 showed that miR-155 signal in infiltrating T lymphocytes was of comparable intensity as in surrounding macrophages (Online Figure IIIC) . These findings are consistent with previous studies showing specificity of miR-155 for hematopoietic cells and upregulation during activation of virtually all leukocyte subtypes, including macrophages and T cells. 13, 15, 24, 25 To compare miR-155 expression in inflammatory cells to that of cardiac resident cells, we measured miR-155 in a cell panel including neonatal (rat) cardiomyocytes and fibroblasts, mouse endothelial cells (SVEC), mouse bone-marrow derived macrophages (BMM), and splenic T lymphocytes. Cells were incubated for 24 hours with proinflammatory stimuli to recapitulate the cardiac inflammatory environment: TNF-␣ for myocytes, fibroblasts, and endothelial cells; LPS for BMM; and concanavalin A for T cells. Expression of miR-155 was most pronounced in activated macrophages and T lymphocytes (over 100-fold higher than for cardiomyocytes; Online Figure VIC) . Expression of miR-155 was low in cardiomyocytes, endothelial cells, and fibroblasts at baseline, and only induced in fibroblasts by TNF-␣ stimulation. In conclusion, miR-155 is mainly localized in inflammatory cells during VM in both mice and humans.
LNA-Anti-miR Inhibits miR-155 Function In Vivo
We next asked whether the known inflammatory effects of miR-155 contribute to a beneficial immune response or to adverse inflammation and cardiac injury during VM. Therefore, we inhibited miR-155 in vivo in inflammationsusceptible C3H mice during the first 7 days of VM. Three individual doses of LNA-anti-miR targeting mouse miR-155 or LNA control were administered on days 1, 4, and 6 after CVB3 inoculation to continuously inhibit miR-155 throughout the hematopoietic proliferative response ( Figure 4A ). Northern blotting showed marked induction of miR-155 during VM and revealed that mature miR-155 was sequestered in a heteroduplex by the LNA-anti-miR-155, as evidenced by a band shift of the mature miR-155 ( Figure 4B ). The qRT-PCR for miR-155 confirmed significant knockdown in the inflamed heart (72%, PϽ0.001). Knockdown was significant but modest in sham hearts (30%, PϽ0.01) and more pronounced in sham spleens that have a high miR-155 expression (Online Figure VIIA and VIIB) . We verified functional cardiac miR-155 inhibition in an unbiased way using Affymetrix microarrays, which showed that mRNAs with canonical 3Ј UTR seed-match sites for miR-155 were derepressed in VM animals treated with LNA-anti-155 in comparison with those from LNA control treated hearts ( Figure 4D and Online Figure VIIC ). Significantly upregulated genes included validated miR-155 targets such as activation-induced cytidine deaminase (AID), and the transcription factors BACH1, Jumonji AT rich interactive domain 2 (JARID2), and CCAAT/enhancer binding protein beta (C/EBP-␤). In agreement, unsupervised clustering could differentiate LNA-anti-155 versus LNA scrambled-treated animals with VM but not sham animals ( Figure 4E ). To investigate anti-miR biodistribution, we injected a FAMlabeled fluorescent LNA-anti-miR-155 in a parallel group of animals, and could detect its accumulation in cardiac myo- cytes and endothelial borders as well as in circulating monocytes, lymphocytes, and neutrophils ( Figure 4F and 4G). Together, these data confirm that miR-155 was inhibited by LNA-anti-155 treatment in VM animals.
Inhibition of miR-155 Reduces Cardiac Injury and Inflammation During VM
At day 7 after infection, miR-155 inhibition significantly reduced cardiac inflammation and necrosis ( Figure 5A and 5B). In agreement, miR-155 inhibition significantly attenuated heart weight increase during VM, a marker of cardiac inflammatory edema ( Figure 5C and Online Table VI ). Suppression of miR-155 additionally reduced body weight loss associated with systemic illness, as well as the numbers of circulating leukocytes induced by CVB3 infection ( Figure  5D and 5E). We next analyzed the effect of miR-155 inhibition on cardiac recruitment of inflammatory cells using immunohistochemistry. MiR-155 inhibition significantly reduced the number of CD11b-stained monocyte-macrophages and Ly6-stained neutrophils and reduced CD3-stained T cells by trend (Pϭ0.09) ( Figure 6A and 6B and Online Figure  VIIIA) . These findings were in keeping with reduced transcripts of CD11b, Ly6G, and CD3 (Online Figure VIIIB) , and a more than 50% reduction of the cytokines interferon beta (IFN-␤), IFN-␥, interleukin-6 (IL-6), and tumor necrosis factor ␣-␣ (TNF-␣) ( Figure 6C and Online Figure VIIIC) . The expression of the anti-inflammatory cytokine Il-10 as well as the markers for alternatively activated antiinflammatory macrophages Arginase and YM-1 were markedly reduced by miR-155 inhibition, while Il-17 levels were around the detection limit and thus too low for reliable quantification. Finally, cardiac CVB3 genomes were lower in Figure VIIIC) .
LNA-anti-miR-155 treated hearts than in controls (Online
To better characterize the effects of miR-155 inhibition on immune cell subtypes, we performed flow cytometry on the cardiac immune cell fraction at day 7 of VM. Flow cytometry revealed that LNA-anti-miR-155 treatment markedly reduced the activation of CD4 ϩ and CD8 ϩ T lymphocytes (Figure 7 and Online Table VII ). The percentages of naïve (CD62L high CD44 low ) T cells in LNA-anti-miR-155-treated versus LNA control-treated hearts were 21.7% versus 4.2%, and 26.6% versus 10.0% for CD4 ϩ and CD8 ϩ T cells, respectively. Proportions of Foxp3 ϩ CD25 ϩ regulatory T cells did not differ between treatment groups. Flow cytometry confirmed that miR-155 inhibition suppressed infiltrating monocytes, without affecting the proportion of proinflammatory Ly6C high monocytes. Together, these data suggest that the attenuation of the immune response after miR-155 suppression is broad and involves both the innate and adaptive immune systems, rather than supporting a preferential activation of antiinflammatory cells or signaling.
Anti-miR-155 Treatment Derepresses the Direct miR-155 Target PU.1 in Cardiac Inflammatory Cells
We next performed Western blots on previously confirmed direct miR-155 targets, whose derepression in leukocytes could explain protection by anti-miR treatment. Expression of PU.1 (an inhibitor of dendritic cell antigen presentation to T cells 26 ), and SHIP1 (a regulator of myeloid proliferation 27, 28 ), was hardly detectable in sham hearts but increased with severity of inflammation, in agreement with their expression by inflammatory cells (Online Figure IX) . Since the extent of cardiac inflammation might thus confound protein levels in whole hearts, we focused on protein levels in isolated cardiac immune fractions. Protein expression of PU.1 was significantly increased in cardiac leukocytes after inhibition of miR-155, while SHIP1 derepression was not statistically significant ( Figure 6D ).
Inhibition of miR-155 Inhibition Does Not Directly Affect Viral Replication or Myocyte Viability
To investigate whether miR-155 inhibition directly impacts CVB3 load or early cytokine signaling by cardiac resident cells, we euthanized animals at day 4 after infection, before onset of inflammation. We found no significant differences in viral load between treatments in the heart, spleen, or liver (Online Figure XA) . Also, miR-155 inhibition did not affect cardiac expression of cytokines, including TNF-␣, Il-6, Il-12a, Il-10, IFN-␤, IFN-␥, and the chemokine macrophage chemo-attractant protein-1 (MCP-1) at this time point (Online Figure XB ). In addition, in vitro knockdown of miR-155 prior to CVB3 infection did not affect cell death, caspase 3 cleavage, or viral replication in neonatal rat cardiomyocytes (Online Figure XI) . These data support the idea that the adverse effects of miR-155 during VM are leukocyteautonomous and independent from viral load in cardiomyocytes, myocyte viability, or cardiac cytokine signaling prior to infiltration by inflammatory cells.
Prolonged Inhibition of miR-155 During Myocarditis Improves Survival and Cardiac Function
To assess the long-term effects of miR-155 inhibition during VM, we followed mice for 7 weeks after CVB3 infection. Treatment with miR-155 inhibitors significantly reduced mortality (1 of 20 versus 6 of 20) (Figure 8 and Online Table  VI ). In addition to decreasing mortality, miR-155 inhibition improved cardiac function in animals surviving after 7 weeks (fractional shortening 23.4% versus 18.4%) (Figure 8 and Online Table VIII ). RNA analysis revealed complete viral elimination in both groups and a trend to reduced induction of cardiac fetal gene markers (ANF, BNP), although this was not statistically significant. Cardiac fibrosis was similar in both groups after 7 weeks though early fibrosis at 1 week was reduced by miR-155 inhibition (Figure 8 and Online Figure  XII) . In conclusion, miR-155 inhibition improved mortality and cardiac function after long-term treatment.
Discussion
This study is the first to investigate microRNA (miRNA) expression profiles related to cardiac virus infection and resulting inflammation in both mice and humans. We identify microRNA-155 as a key contributor to exaggerated antiviral surveillance.
Two of the most important questions in myocarditis research are (1) why infection by cardiotropic viruses triggers myocarditis in some patients while remaining asymptomatic in others, and (2) what signaling pathways contribute to cardiac injury during the inflammatory response, since distinct components of the inflammatory response can contribute to either efficient viral elimination and cardiac protection, or to irreversible cardiac damage and functional deterioration in VM. 2, 29, 30 The current study addresses these questions by establishing a set of susceptibility-and inflammation-related miRNAs in mice, and identifying miR-155 as a contributor to adverse inflammation during VM both in mice and human VM. Moreover, our results suggest therapeutic opportunities by targeting miR-155 in mice to limit cardiac injury and mortality in VM.
The proinflammatory effects of miR-155 in B and T lymphocytes as well as macrophages and dendritic cells have been well established. MiR-155 expression is induced during activation of both macrophages and lymphocytes. 14, 15 In lymphocytes, miR-155 promotes Th1 responses as well as germinal center formation, 13, 14 while favoring proliferation and proinflammatory cytokine secretion in myeloid cells. 27, 31 MiR-155 also mediated crosstalk between innate and adaptive immune cells, because miR-155 deficient dendritic cells are less capable of activating T cells. 14, 26 This multitude of proinflammatory effects of miR-155 on both the innate and adaptive immune systems is associated with a variety of anti-inflammatory protein targets, including proteins suppressor of cytokine secretion 1 (SOCS1), 32, 33 SH2-containing inositol-5-phosphatase (SHIP1), 27 AID, 34 and the transcription factors PU.1 35 and c-MAF. 14 In line with these effects, miR-155 was shown to be protective during experimental autoimmune encephalitis (EAE) 36, 37 and rheumatoid arthritis. 28 Most of the immune mechanisms controlled by miR-155 are important in the pathogenesis of VM. However, because VM pathogenesis involves viral pathogens, protective effects of anti-inflammatory manipulations are not trivial. In the current study, pharmacological inhibition of miR-155 reduced both cardiac damage and mortality during VM, indicating that miR-155 signaling contributes to an adverse rather than beneficial immune activation in the context of VM. Anti-miR treatment reduced cardiac numbers of monocytemacrophages and inhibited T lymphocyte activation, in parallel with downregulation of both pro-and anti-inflammatory cytokines, including TNF-␣, Il-6, IL-10, and IFN-␥ during the inflammatory phase. The increased percentage of naïve T cells in LNA-anti-miR-155-treated animals was in line with the derepression of PU.1, a direct miR-155 target that inhibits antigen presentation to lymphocytes in dendritic cells. 26 Cardiac protection by miR-155 inhibition was likely immune- cell autonomous, since miR-155 inhibition did not affect viral load, myocyte viability, or cytokine signaling by cardiac resident cells prior to infiltration by immune cells. Our results therefore suggest that therapeutic targeting of miR-155 may benefit myocarditis patients by dampening inflammation. Of note, miR-155 has been described to target the angiotensin II type 1 receptor (AT1R). 38 Although we did not observe increased fibrosis after miR-155 inhibition, clinical studies are required to exclude short-term side effects of anti-miR-155 treatment.
Beside miRNA-155, we identified a set of miRNAs that is consistently upregulated during acute inflammation of both human and mouse VM, including miR-155, miR-146b, and miR-21, which all have central functions in immune activation and inflammation, 21, 39 and the less well-known miR-130b, a virus-induced inhibitor of target cell apoptosis in humans. 40 MiR-106a was upregulated in both C3H and C57Bl/6N at day 7 postinfection. MiR-106a has been shown to target interleukin-10, a central regulator of the immune system, 41 while the expression of miR-106a itself is regulated by the transcription factors Egr-1 and Sp-1, both key in cardiac processes. 41 Immune functions have also been described for consistently downregulated candidates: miR-107 is downregulated in multiple cell types in response to TLR-4 Figure 7 . MiR-155 inhibition suppresses T lymphocyte activation in myocarditis hearts. A, Flow cytometry of the cardiac immune fraction. MiR-155 inhibition significantly increased the percentage of naïve (CD62L high CD44 low ) versus effector/ effector-memory (CD62L low CD44 high ) CD4 ϩ and CD8 ϩ T lymphocytes in myocarditis hearts (LNA-anti-miR-155 versus LNA control: 21.7% versus 4.2% and 26.6% versus 10.0% for CD4 ϩ and CD8 ϩ , respectively). B, The amount of Foxp3 ϩ CD25 ϩ regulatory T cells was not different between treatment groups. C, MiR-155 inhibition significantly reduced the percentage of monocytes of the cardiac infiltrates, but did not affect the proportion of proinflammatory Ly6C high monocytes (nϭ4 per sham group and nϭ8 per VM group). *PϽ0.05, **PϽ0.01, ***PϽ0.001.
Figure 8. MiR-155 inhibition protects against mortality and systolic dysfunction in viral myocarditis. A, Kaplan-Meier curve
showing reduced mortality after miR-155 inhibition in comparison with controls (1 of 20 versus 6 of 20, respectively; PϽ0.05). B, Fractional shortening was decreased in VM control hearts at weeks 2 and 7 in comparison with shams, but not in miR-155 inhibited VM hearts. After 7 weeks, fractional shortening was significantly higher in LNA-anti-miR-155 versus LNA control animals (23.4% versus 18.4%, respectively; PϽ0.05). C, The cardiac increase in fetal gene markers in surviving animals was attenuated by miR-155 inhibition, although this difference was not statistically significant. We did not observe differences in cardiac collagen deposition between anti-miR treatment groups (D) (nϭ6 per sham group and nϭ20 per VM group). *PϽ0.05, **PϽ0.01. signaling and is required to facilitate macrophage adhesion, 42 whereas inhibition of miR-99b reduces dendritic cell differentiation. 22 In addition, we identified a set of miRNAs exclusively associated with viral infection in resistant C57Bl6/N mice, including miR-483*, miR-411, miR-135*, miR-300 and miR-140, miR-93*, and miR-17*. While these miRNAs are relatively unknown, their likely involvement in the primary response to viral infection and disease susceptibility invites future studies.
In conclusion, VM induces marked miRNA expression changes in mouse and human hearts. MiRNA-155 is upregulated in myeloid and lymphoid inflammatory cells during acute VM and is a mediator of adverse cardiac immune activation. In vivo inhibition of microRNA-155 after CVB3 infection attenuates myocardial inflammation and necrosis, reduces mortality, and improves cardiac function. As such, this study identifies miRNA-155 as a novel therapeutic target for treatment of viral myocarditis.
